Therapeutics for Gastroesophageal Adenocarcinoma: Application, Translation and Discovery - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  Therapeutics for Gastroesophageal Adenocarcinoma: Application, Translation and Discovery

SU2C-Torrey Coast Foundation Gastroesophageal Cancer Research Team: Therapeutics for Gastroesophageal Adenocarcinoma: Application, Translation and Discovery

January 2023-December 2027

The SU2C-Torrey Coast Foundation Gastroesophageal Cancer Dream Team Collective includes three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer in diverse populations. This Collective aims to foster new and inclusive cancer research on the causes and treatments of gastroesophageal cancer, mentor a new generation of scientists focused on gastroesophageal cancer research, bring new treatments to the clinic, and provide medical professionals with tools and materials to better advocate for gastroesophageal cancer screening and treatment with their patients. This Research Team is specifically focused on the application, translation and discovery of therapeutics for gastroesophageal adenocarcinoma.

Supported by:

ABOUT THIS TEAM’S RESEARCH

Gastroesophageal adenocarcinoma (GEA) is a leading cause of cancer death. In 2022, there were 20,640 new cases and 16,410 deaths in the US, exceeding deaths from ovarian cancer. Outside of anti-PD1/PDL1 therapy for PDL1+/MSI-hi cancers, and HER2 therapies in HER2+ patients, there has been no significant improvement in patient outcomes. Even among patients predicted to benefit from this treatment, the median improvement in survival is a modest 2-3 months at best. As such, there remains an urgent need for re-envisioning target identification and developing new therapies in this devastating disease. The past 10 years have seen a revolution in the development of cancer therapeutics, which created the basis for this Research Team to uncover new therapeutics and initiate new trials in GEA. The Team plans to do this by: 1) defining and targeting the cell surface of gastroesophageal adenocarcinoma and squamous cell carcinoma, and 2) using functional genomic approaches to identify therapeutic targets in gastroesophageal adenocarcinoma. The Team also plans to develop biparatopic claudin18.2-targeting CAR-T cells for clinical development in claudin 18.2 expressing gastric and esophageal cancers.

MEET THE TEAM

The top scientists and researchers on the SU2C-Torrey Coast Foundation Gastroesophageal Cancer Research Team: Therapeutics for Gastroesophageal Adenocarcinoma: Application, Translation and Discovery come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C-Torrey Coast Foundation Gastroesophageal Cancer Research Team:

TEAM MEMBERS

William Sellers, MD
Broad Institute
Leader

Marcela Maus, MD, PhD
Massachusetts General Hospital
Co-leader

Maura Charlton
Broad Institute
Project Manager

Jason Diaz
Hope for Stomach Cancer
Advocate

TEAM PROGRESS UPDATES

Progress updates will be posted when available.

TEAM PROGRESS UPDATES

PUBLICATIONS

Links to publications will be posted when they are available.

CANCER CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find clinical trial information, answers to common questions, and a free clinical trial finder tool.

LEARN MORE

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.